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ABSTRACT
As a number of disease-modifying anti-rheumatic drugs often have side effects at high doses and/or during long-term administration, 
increased efficacy without increased toxicity is expected for combination therapy of rheumatoid arthritis (RA). The safety of long-
term therapy of RA is very important as patients with RA are usually treated for two or more decades. This experimental overview 
is focused on some promising substances and their combinations with the standard antirheumatic drug – methotrexate (Mtx) for 
treatment of rheumatoid arthritis. The adjuvant arthritis model in Lewis rats was used for evaluation of antiinflammatory efficacy of 
the substances evaluated. Mtx was administered in the oral dose of 0.3 mg/kg b.w. twice a week. Natural and synthetic antioxidants 
were administered in the daily oral dose of 20 mg/kg b.w for coenzyme Q10 (CoQ10), 150 mg/kg b.w for carnosine (Carn), 15 mg/kg 
b.w. for stobadine dipalmitate (Stb) and its derivative SMe1.2HCl (SMe1), and 30 mg/kg b.w. for pinosylvin (Pin) or pterostilbene (Pte). 
Mtx in the oral dose of 0.4 mg/kg b.w. twice a week was combined with Pin in the oral daily dose of 50 mg/kg b.w. Clinical (hind paw 
volume – HPV), biochemical (activity of GGT in joint and level of TBARS in plasma), and immunological (IL-1 in plasma) parameters 
were assessed. Our results achieved with different antioxidants in monotherapies showed a reduction of oxidative stress in adjuvant 
arthritis independently of the chemical structure of the compounds. Pin was the most effective antioxidant tested in decreasing HPV. 
All combinations tested showed a higher efficacy in affecting biochemical or immunological parameters than Mtx administered in 
monotherapy. The findings showed the benefit of antioxidant compounds for their use in combination therapy with methotrexate. 
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molecules. Most antirheumatics have side-effects when 
used in higher doses and/ or within long-term dosage. 
Combinatory therapy is expected to have a higher efficacy 
without increased toxicity. Mtx has become the main 
immunosuppressive substance used in the treatment of 
patients with RA (Weinblatt, 2003). The use of Mtx has to 
be limited due to its toxic manifestations, e.g. abdominal 
disorder, alopecia, oral ulcers, and cytopenia (Alarcon 
et al., 1989). Ineffectiveness of treatment can be also 
observed. In the survey of McKendry and Dale (1993), due 
to the risk of treatment termination was substantiated in 
75% of patients with RA taking Mtx for 60 months. An 
adverse drug effect proved to be a more common reason 
for treatment termination (53%) compared to loss/lack 
of beneficial effect ( 22% ), other reasons ( 1 6% ), or lost 
Introduction 
This experimental overview is focused on some promis-
ing substances and their combinations with the standard 
antirheumatic drug methotrexate (Mtx) for treatment 
of rheumatoid arthritis (RA). Preclinical research on 
animal models of RA is very important for alerting the 
healthcare and scientific community, as well as pharma-
ceutical companies, of the existence of new or “forgotten” 
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to follow-up (9%). On the other hand, the therapeutic 
efficacy of Mtx can be increased by combination with 
other synthetic drugs or inhibitors of TNF-α (Smolen et 
al., 2010). Application of biological therapy (antibodies 
or soluble receptors of TNF-α, IL-1 and IL-6) represents 
a great progress in the therapy of RA, while biological 
treatment is also frequently combined with Mtx (Maini 
et al., 1998; Weinblatt et al., 1999). There are countless 
possibilities for combinations with Mtx. Many substances 
were neglected when they failed to show good efficacy 
in monotherapy compared to standard antirheumatics. 
They would not get a second chance if the expected 
reduction of clinical parameters (mainly edema of joints) 
did not materialize, despite the fact that they improved 
many biochemical disease markers. This overview is 
focused mostly on substances of natural origin possess-
ing antiinflammatory and antioxidative properties along 
with minimal side effects when administered to animals. 
The safety of long-term therapy of RA is very important 
as patients with RA are usually treated for two or more 
decades. 
In our experiments of the last five years, synthetic 
(pyridoindoles) and natural substances (polysaccharides: 
glucomannan, beta-glucan; endogenous molecules: 
coenzyme Q10 and carnosine; different substances and 
products of plant origin) with immunomodulatory and 
antioxidative effects were assessed in monotherapy 
by using experimental adjuvant arthritis (AA). These 
active substances decreased the progression of AA when 
administered to arthritic rats over the period of 28 days 
(Bauerova  et al., 2005a; 2005b; 2008a; 2008b; 2009; 
Drabikova et al., 2009; Drafi et al., 2010; Jančinova et al., 
2009; Kogan et al., 2005; Mačičkova et al., 2010; Poništ 
et al., 2010; Sotnikova et al., 2009; Štrosova et al., 2008; 
2009). Recently we focused on combined therapy with 
Mtx and confirmed the potent effect of this drug in sev-
eral experiments administered along with an appropriate 
antioxidative substance (Bauerova et al., 2010; Jančinova 
et al., 2010; Rovensky et al., 2009a).
The primary beneficial effect concerned the reduc-
tion of articular edema and normalization of bio-
chemical parameters were also reported by other authors 
(Cuzzocrea et al., 2005; Kogure et al., 2010; Rovensky et 
al., 2002; 2008; 2009b). 
In this overview, our results obtained in AA with 
endogenous (coenzyme Q10 and carnosine) and synthetic 
(stobadine and SMe1) antioxidants as well as two selected 
compounds from plants (pterostilbene and pinosylvin) 
will be completed with new unpublished results. The aim 
is to demonstrate the potential of antioxidant compounds 
for their use in combination therapy with Mtx. 
Methods
Animals, experimental design and treatments
Male Lewis rats weighing 160–180  g were obtained 
from the Breeding Farm Dobra Voda, Slovakia. The 
rats had free access to standard pelleted diet and tap 
water. The experimental protocol was approved by 
the Ethics Committee of the Institute of Experimental 
Pharmacology and Toxicology and by the Slovak State 
Veterinary and Food Administration. Adjuvant arthritis 
(AA) was induced by a single intradermal injection of 
heat-inactivated Mycobacterium butyricum in incomplete 
Freund’s adjuvant (Difco Laboratories, Detroit, MI, USA). 
The injection was performed near the tail base. The 
experiments included healthy animals (HC), arthritic 
animals not treated (AA), arthritic animals treated with 
methotrexate in the oral dose of 0.3  mg/kg b.w. twice a 
week (AA-Mtx), arthritic animals treated with coen-
zyme Q10 (CoQ10) in the daily oral dose of 20 mg/kg b.w 
(AA-CoQ10), arthritic animals treated with carnosine in 
the daily oral dose of 150 mg/kg b.w (AA-Carn), arthritic 
animals treated with the combination of CoQ10 and 
methotrexate (AA-CoQ10+Mtx), arthritic animals treated 
with stobadine dipalmitate (AA-Stb) or its derivative 
SMe1.2HCl (AA-SMe1) in the oral daily dose of 15 mg/kg 
b.w., arthritic animals treated with the combination of 
stobadine dipalmitate and methotrexate (AA-Stb+Mtx), 
arthritic animals treated with pinosylvin (AA-Pin) or 
pterostilbene (AA-Pte) in the oral daily dose of 30 mg/kg 
b.w., arthritic animals treated with the combination of 
pinosylvin and methotrexate (AA-Pin+Mtx). In the latter 
combination, arthritic animals were treated twice a week 
with methotrexate in the oral dose of 0.4 mg/kg b.w. and 
daily with pinosylvin in the oral dose of 50  mg/kg b.w.. 
Monotherapy was performed with the same doses.
Methotrexat® Lachema 50 sol. inj. was used. CoQ 10 
in the form of Li-Q-Sorb® was purchased from Tishcon 
Corp., USA. Carn was purchased from Hamary Chemicals 
Ltd., Japan. The pyridoindoles were synthetized by Ing. 
Vladimir Snirc, PhD. Pin and Pte were synthetized in the 
Institute of Organic Chemistry and Biochemistry, Prague, 
Czech Republic.
In each experimental group 8–10 animals were used. 
The duration of the experiments was 28 days. After the 
animals had been sacrificed under deep ketamin/xylasine 
anesthesia, blood for plasma preparation and tissue for 
hind paw joint homogenate preparation were taken on day 
28. Plasma was stored at minus 70 °C until biochemical 
and immunological analysis.
Clinical parameter evaluated: hind paw volume
We monitored the basic clinical parameter: hind paw 
volume (HPV). The HPV increase was calculated as the 
percentage increase in HPV on the experimental day 28 
relative to the HPV at the beginning of the experiment. 
Hind paw volume was recorded with the use of an elec-
tronic water plethysmometer (UGO BASILE, Comerio-
Varese, Italy). 
Rat IL-1α assay in plasma
For determination of IL-1α in plasma an ELISA kit from 
Bender MedSystems was used as described in the product 
manual Rat IL-1α ELISA BMS627 and BMS627TEN. 
The rat IL-1 ELISA is an enzyme-linked immunosorbent 
assay for quantitative detection of rat IL-1. Rat IL-1 35
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present in the samples binds to anti-rat IL-1antibodies 
adsorbed to the microwells. The reaction of a secondary 
biotin-conjugated anti-rat IL-1 antibody is evaluated by 
Streptavidin-HRP. Tetramethyl-benzidine oxidation 
with HRP bound to the immune complex was measured 
at 490  nm against reference wavelength of 620  nm. The 
results were calculated from a standard calibration curve 
obtained for internal standards.
Tissue activity of cellular γ-glutamyltransferase from hind paw
The activity of cellular γ-glutamyltransferase (GGT) in 
hind paw joint tissue homogenate was measured by the 
method of Orlowski & Meister ( 1970) as modified by 
Ondrejickova et al. (1993). Samples were homogenized 
in a buffer at 1  :  9 w/v (buffer composition: 2.6  mM 
NaH2HPO4; 50  mM Na2HPO4; 15  mM EDTA; 68  mM 
NaCl; pH 8.1) by Ultra Turax TP 18/10 (Janke & Kunkel, 
Germany) for 1 min at 0 °C. Substrates (8.7 mM γ-glutamyl-
p-nitroanilide (γ-GPN); 44 mM methionine) were added 
in 65% isopropylalcohol to final concentrations of 2.5 mM 
and 12.6 mM, respectively. After incubation for 60 min at 
37 °C, the reaction was stopped with 2.3 ml cold methanol 
and the tubes were centrifuged for 20 min at 5000 rpm. 
Absorbance of supernatant was measured in a Hewlett 
Packard Vectra 286/12 spectrophotometer in 0.5  cm 
cuvette at 406 nm. Reaction mixtures in the absence of 
either the substrate or acceptor were used as reference 
samples.
Thiobarbituric acid reactive substances in plasma 
TBARS were measured in heparinized blood plasma 
(Brown & Kelly, 1996). The amount of 750  μl of 0.67% 
thiobarbituric acid, 750  μl of 20% trichloroacetic acid, 
350 μl of phosphate buffer (pH 7.4) were added to 150 μl 
of plasma, then mixed and incubated in a water bath at 
90 °C for 30 min. The reaction was stopped by dipping the 
test tubes into ice for 10 min. Samples were centrifuged at 
3 000 rpm. The supernatant was removed and absorbance 
measured at 535 nm in a 0.5 cm cuvette.
Statistical analysis of data
The data for all parameters are expressed as arithmetic 
mean ± S.E.M. For significance calculations unpaired 
Student`s  t-test was used with *p<0.05 (significant), 
**p<0.01 (very significant), ***p<0.001 (extremely sig-
nificant). The arthritis group was compared with healthy 
control animals (*). The treated arthritis groups were 
compared with untreated arthritis (+). The combination 
treatment was compared to individual Mtx treatment (#).
Results
Of the antioxidants administered in monotherapy 
to arthritic ra ts only pinosylvin sho w ed a significan t  
reduction of HPV. There were no big differences in the 
effectivity of antioxidants in the groups compared (CoQ 
versus Carn, and Stb versus SMe1), except in the group of 
stilbenoids where Pin exhibited a notably higher efficacy 
than Pte (Figure 1). In all combination therapies, HPV was 
more effectively reduced than by Mtx alone. This effect 
was most noticeable for the combination of Mtx and Stb 
(Figures 2–4). All combination therapies achieved a sig-
nificantly higher efficacy in affecting selected immuno-
logical (IL-1α – Figure 5) and biochemical (GGT – Figure 
6 and TBARS – Figure 7) parameters compared to Mtx 
alone.
Discussion
Rheumatoid arthritis (RA) is a common severe joint dis-
ease affecting all age groups. It is thus of great importance 
to develop new strategies for its treatment. As a number 
of disease-modifying anti-rheumatic drugs (DMARDs) 
often have side effects at high doses and/or during 
long-term administration, increased efficacy without 
increased toxicity is expected for combination therapy 
of RA. Methotrexate (Mtx), a folic acid antagonist, has 
become the predominant immunosuppressive agent used 
in the treatment of patients with RA (Williams et al., 
1985). Mtx acts mainly on actively proliferating cells dur-
ing the S-phase of proliferation, suppresses macrophage 
function, modulates interleukin-1 (IL-1) and superoxide 
anion production, and inhibits neutrophil chemotaxis 
(Moreland et al., 1997). Furthermore, Mtx treatment was 
shown to decrease synovial collagenase gene expression in 
patients with RA (Genestier et al., 2000). The use of Mtx 
has been limited by some of its toxic manifestations, such 
as abdominal discomfort, alopecia, oral ulcerations, and 
cytopenia (Alarcon et al., 1989). In clinical studies, inflix-
imab or etanercept have been used in combination with 
methotrexate to produce greater efficacy of the treatment 
of RA (Maini et al., 1998; Weinblatt et al., 1999). TNF-α 
blockers may be used alternatively with other candidates 
for RA combination therapy. As resulted from our previ-
ous experiments (Bauerova et al., 2005a; 2005b; 2008a; 
2008b; 2009; Drábikova et al., 2009; Dráfi et al., 2010; 
Jančinova et al., 2009; Kogan et al., 2005; Mačičkova et al., 
2010; Poništ et al., 2010; Sotnikova et al., 2009; Štrosova 
et al., 2008; 2009), all performed in the adjuvant arthritis 
model, substances with antioxidant properties have a high 
potency to be used in combination therapy with Mtx. 
For our experiments, we chose substances with anti-
oxidative properties and low toxicity. Administration of 
CoQ10 significantly improved changes of rat body mass, 
reduced HPV, and prevented CoQ imbalance in skeletal 
muscle mitochondria. The significantly improved myo-
cardium mitochondrial function indicated that CoQ10 
supplementation may protect cardiac function also in 
patients with RA (Bauerova et al., 2008b). Based on our 
results with mitochondrial energetics modification and 
the observed antiinflammatory and antioxidant effects 
(Gvozdjakova et al., 2004; Bauerova et al., 2005a; 2008b; 
Poništ et al., 2007), CoQ10 was selected as a candidate for 
combinatory therapy of RA. Another endogenous antioxi-
dant used – carnosine, an essential endogenous molecule, 
has many physiological functions: radical scavenging, 36
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pH buffering, heavy metal chelating, anti-glycating, and 
neutralizing toxic aldehydes. Carn was found to have 
neuroprotective, hepatoprotective, cataract treating, and 
anti-aging abilities (Boldyrev, 2005), but its antiinflam-
matory potential in autoimmune systemic inflammatory 
diseases, as RA, has been scarcely investigated as yet. The 
first experiment with Carn in AA was performed in our 
laboratories. Carn beneficially affected HPV measured 
in time profile (14, 21 and 28 days), significantly on day 
14 when the clinical manifestation of the disease started. 
Carn was able to delay the disease onset, however it was 
not so effective later on (days 21 and 28) when AA was 
fully developed. The markers of redox imbalance in 
plasma (TBARS and protein carbonyls) were significantly 
decreased, indicating the ability of Carn to restore redox 
balance in vivo (Dráfi et al., 2010). Stobadine dipalmitate 
(Stb) belongs to the group of naturally occurring carbo-
lines (pyridoindoles – PI), tricyclic compounds of indole 
structure with a side ring comprising another nitrogen 
atom. Unlike α- and β-carbolines, it does not reveal any 
obvious toxic effects and possesses antioxidant activity. 
Stb, (–)-cis-2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-1H-
pyrido[4,3b]indole, was developed and synthesized in a 
search for new antidysrhythmic drugs at the Institute of 
Experimental Pharmacology, Slovak Academy of Sciences 
in Bratislava, Slovakia, in 1983 (Štolc et al., 1983). Later also 
the PI derivative SMe1.2HCl: 8-methoxy-2,3,4,4a,5,9b-
hexahydro-1H-pyrido[4,3b]indole was synthesized at our 
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Figure 1. Reduction of hind paw volume on day 28 – treatment 
with diff  erent antioxidants. Values are given as arithmetic mean 
of percentage ± S.E.M. of reduction of hind paw volume calcu-
lated to untreated arthritic rats (100% represented by dot-and-
dash line). Statistical signifi  cance was evaluated using unpaired 
Student´s t-test: +p<0.05 with respect to untreated arthritic ani-
mals.
Figure 2. Eff  ect of combined therapy of methotrexate and coen-
zyme Q10 on hind paw volume assessed on day 28. Values are 
given as arithmetic mean ± S.E.M. Statistical signifi  cance was 
evaluated using unpaired Student´s t-test: ***p<0.001 with 
respect to control healthy animals, ++p<0.01 and +++p<0.001 
with respect to untreated arthritic animals. The experiment 
included healthy control animals (HC), arthritic animals with-
out any drug administration (AA), and arthritic animals with the 
administration of coenzyme Q10 (AA-CoQ), methotrexate (AA-
Mtx) and combination of methotrexate and coenzyme Q10 (AA-
CoQ+Mtx).
Figure 3. Eff  ect of combined therapy of methotrexate and sto-
badine on hind paw volume assessed on day 28. Values are given 
as arithmetic mean ± S.E.M. Statistical signifi  cance was evalu-
ated using unpaired Student´s t-test: ***p<0.001 with respect 
to control healthy animals, +p<0.05 with respect to untreated 
arthritic animals and #p<0.05 for comparison of methotrexate 
monotherapy with combined therapy. The experiment included 
healthy control animals (HC), arthritic animals without any drug 
administration (AA), and arthritic animals with the administra-
tion of methotrexate (AA-Mtx) and combination of methotrexate 
and stobadine (AA-Stb+Mtx).
Figure 4. Eff  ect of combined therapy of methotrexate and pino-
sylvin on hind paw volume assessed on day 28. Values are given 
as arithmetic mean ± S.E.M. Statistical signifi  cance was evalu-
ated using unpaired Student´s t-test: ***p<0.001 with respect to 
control healthy animals, +++p<0.001 with respect to untreated 
arthritic animals. The experiment included healthy control ani-
mals (HC), arthritic animals without any drug administration 
(AA), and arthritic animals with the administration of pinosylvin 
(AA-Pin), methotrexate (AA-Mtx) and combination of methotrex-
ate and pinosylvin (AA-Pin+Mtx).37
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institute. The first results with Stb in rat AA were obtained 
when its protective effect against indomethacin-induced 
gastroenteropathy was evaluated (Bauerova et al., 2004).
Pinosylvin [3´,5´-dihydroxystilbene] and pterostil-
bene [3,5-dimethoxy-4´-hydroxystilbene] are natural 
substances from the stilbenoid group, wide-spread in a 
variety of plants. They are chemically related to resvera-
trol. Both substances studied inhibited significantly the 
chemiluminescence (CL) of whole human blood and the 
CL of isolated human neutrophils (Perečko et al. 2008). 
The new information on the inhibitory effect of Pin and 
Pte on HPV, ROS and MPO activity suggests that the 
protective effect of Pin may be beneficial in controlling 
inflammation in experimental AA (Mačičkova et al., 
2010).
The situation for adjuvant arthritis is complicated 
due to the dominant involvement of Th-1-driven autoim-
mune etiopathology. Oxidative stress (OS) in this animal 
model occurs as a reaction to autoimmune processes. 
Under these conditions, control of OS is of secondary 
importance, although it could enhance immunomodula-
tory therapy of RA. We therefore administered CoQ10 
(Bauerova et al., 2010) or Stb (our unpublished results) 
or Pin in combination with Mtx (Jančinova et al., 2010 
and our unpublished results). The basic clinical param-
eter – HPV – was improved independently of the type of 
antioxidant used, although Pin seems to be more active 
than Stb or CoQ10 (Figure 1). Interestingly, on comparing 
all pairs of substances tested, namely CoQ10 with Carn, 
Stb with SMe1, and Pin with Pte (Figure 1), there were 
no significant differences between the two endogenous 
antioxidants or two pyridoindoles, but the two stilbenoids 
exhibited a great difference in their capacity to suppress 
the hind paw edema in AA. In all combination treatments, 
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Figure 5. Eff  ect of combined therapy of methotrexate and coen-
zyme Q10 on plasmatic level of IL-1α assessed on day 28. Values 
are given as arithmetic mean ± S.E.M. Statistical signifi  cance was 
evaluated using unpaired Student´s t-test: **p<0.01 with respect 
to control healthy animals, ++p<0.01 with respect to untreated 
arthritic animals and ##p<0.01 for comparison of methotrexate 
monotherapy with combined therapy. The experiment included 
healthy control animals (HC), arthritic animals without any drug 
administration (AA), and arthritic animals with the administra-
tion of coenzyme Q10 (AA-CoQ), methotrexate (AA-Mtx) and 
combination of methotrexate and coenzyme Q10 (AA-CoQ+Mtx).
Figure 6. Eff  ect of combined therapy of methotrexate and sto-
badine on activity of GGT in joint homogenate assessed on day 
28. Values are given as arithmetic mean ± S.E.M. Statistical signifi  -
cance was evaluated using unpaired Student´s t-test: ***p<0.001 
with respect to control healthy animals, +++p<0.001 with 
respect to untreated arthritic animals and ##p<0.01 for compari-
son of methotrexate monotherapy with combined therapy. The 
experiment included healthy control animals (HC), arthritic ani-
mals without any drug administration (AA), and arthritic animals 
with the administration of methotrexate (AA-Mtx) and combina-
tion of methotrexate and stobadine (AA-Stb+Mtx).
Figure 7. Eff  ect of combined therapy of methotrexate and pino-
sylvin on plasmatic level of TBARS assessed on day 28. Values 
are given as arithmetic mean ± S.E.M. Statistical signifi  cance 
was evaluated using unpaired Student´s t-test: ***p<0.001 with 
respect to control healthy animals, +++p<0.001 with respect to 
untreated arthritic animals and #p<0.05 for comparison of meth-
otrexate monotherapy with combined therapy. The experiment 
included healthy control animals (HC), arthritic animals without 
any drug administration (AA), and arthritic animals with the 
administration of pinosylvin (AA-Pin), methotrexate (AA-Mtx) 
and combination of methotrexate and pinosylvin (AA-Pin+Mtx).
HPV was more effectively reduced than by individual Mtx 
treatment (Figures 2–4). 
For further evaluation of the efficacy of CoQ10+Mtx 
administration, we analyzed IL-1α in plasma, which is one 
of the most important pro-inflammatory cytokines. IL-1 
is closely related to inflammation and articular damage 
in several arthritis models and it is therefore generally 
accepted that IL-1 has a pivotal role in the pathophysiol-
ogy of rheumatoid arthritis. In particular, IL-1 is a potent 
stimulator of synoviocytes, chondrocytes and osteoblasts. 38
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Moreover, IL-1 is a key mediator of synovial inflamma-
tion and pannus formation (Dinarello & Moldawer, 2002). 
Figure 5 shows the effects of the given treatments on 
AA-increased IL-1α levels. The improving effect on the 
increased cytokine plasmatic levels is rising in the order 
CoQ10, Mtx and CoQ10+Mtx. Furthermore, a statistically 
significant difference favored the combination of Mtx 
with CoQ10 , compared to Mtx monotherapy.
GGT is an important component of inflammatory 
processes since its activity is closely connected with the 
overall antioxidant status of the organism. We found that 
the activity of GGT was approx. 3–6 times higher in AA 
animals than in healthy controls in the spleen and 1.4–2.3 
higher in the joint (Bauerova et al., 2006; 2008a; 2009; 
Sotnikova et al., 2009). W e assume that the increased 
activity of GGT in AA is a result of elevated systemic oxi-
dative stress. Stb was significantly effective in suppressing 
the increased activity of GGT in the joint, as expected 
from its antioxidant potential (Poništ et al., 2010). The 
addition of Stb to Mtx caused significant improvement 
in lowering this biochemical parameter compared to Mtx 
monotherapy (Figure 6).
A frequently used marker of lipid peroxidation is MDA 
assessed as an adduct with TBA. Clinical studies have 
shown increased plasmatic levels of MDA in patients with 
RA (Baskol et al., 2005; 2006; Sarban et al., 2005). In ani-
mal models of AA, the level of MDA was elevated in the 
plasma of arthritic animals (Tastekin et al., 2007; He et al., 
2006; Bauerova et al., 2008a; 2009; Štrosova et al., 2008; 
2009; Sotnikova et al., 2009). The combination of Pin with 
Mtx was more effective in decreasing the plasmatic level 
of TBARS than was Mtx alone (Fig.7). This finding is in 
good agreement with the results of Jančinova et al. (2010) 
showing the combination of the two substances as more 
active in suppressing spontaneous and stimulated chemi-
luminescence in blood of arthritic rats than achieved with 
Mtx administered alone.
Our results obtained with different antioxidants 
in monotherapies showed reduction of OS in adjuvant 
arthritis independently of the chemical structure of 
the compounds or their solubility in lipids (CoQ10) or 
water (Carn). Thus we may conclude that therapeutic 
benefits from antioxidant treatment are primarily bound 
to reduction of systemic OS. All combinations tested 
showed a higher efficacy in affecting biochemical or 
immunological parameters than Mtx administered in 
monotherapy. These results indicate that application of 
supporting immunosuppresive treatment represented by 
Mtx combined with an antioxidative substance appears 
to be a good decision. In our future experiments we will 
try to lower the dose of Mtx in combinations with the 
most effective antioxidants. We expect that a suboptimal 
dose of Mtx with an antioxidant could yield an as good 
efficacy as the optimal dose of Mtx alone in reducing of 
hind paw edema in AA. An effective combination of an 
antioxidant with a lowered dose of Mtx could also reduce 
the toxic side effect of Mtx treatment. Conclusion: We 
demonstrated the benefit of antioxidant compounds for 
their use in combination therapy with methotrexate. 
Acknowledgements
The authors wish to thank Mrs. Denisa Komendova for 
technical assistance and Dr. Magda Kouřilová, PhD. for 
correction of the English language. This work was sup-
ported by grants VEGA 2/0045 / 1 1 ; VEGA 2/0090/08; 
APVV-51-017905; APVV 3015-07
REFERENCES
Alarcón GS, Tracy IC, Blackburn WD Jr. (1989). Methotrexate in rheumatoid 
arthritis. Toxic eff  ects as the major factor in limiting long-term treatment. 
Arthritis Rheum. 32(6): 671–6.
Baskol G, Demir H, Baskol M, Kilic E, Ates F, Kocer D, Muhtaroglu S. (2005). As-
sessment of paraoxonase 1 activity and malondialdehyde levels in patients 
with rheumatoid arthritis. Clin Biochem 38: 951–965.
Baskol G, Demir H, Baskol M, Kilic E, Ates F , Karakukcu C, Ustdal M. (2006). 
Investigation of protein oxidation and lipid peroxidation in patients with 
rheumatoid arthritis. Cell Biochem Funct 24: 307–311.
Bauerova K, Nosalova V, Mihalova D, Navarova J. (2004). Contribution to safe 
anti-infl  ammatory therapy with indomethacin. Cent Eur J Public Health 12: 
S8–S10.
Bauerova K, Kucharska J, Mihalova D, Navarova J, Gvozdjakova A, Sumbalova 
Z. (2005a). Eff  ect of coenzyme Q(10) supplementation in the rat model of 
adjuvant arthritis. Biomed Pap 149(2): 501–503.
Bauerova K, Valentova J, Poništ S, Navarova J, Komendova D, Mihalova D. 
(2005b). Eff  ect of copper complexes on the development of adjuvant ar-
thritis: Therapeutic and toxicological aspects. Biologia 60(17): 65–68.
Bauerova K, Poništ S, Ondrejíčkova O, Komendova D, Mihalova D. (2006). As-
sociation between tissue gamma glutamyl-transferase and clinical markers 
of adjuvant arthritis in Lewis rats. Neuroendocrinol Lett 27: 172–175.
Bauerova K, Poništ S, Navarova J, Dubničkova M, Paulovičova E, Pajtinka M, 
Kogan G, Mihalova D. (2008a). Glucomannan in prevention of oxidative 
stress and infl  ammation occurring in adjuvant arthritis. Neuroendocrinol-
ogy Lett 29(5): 691–696.
B a u e r o v a  K ,  K u c h a r s k a  J ,  P o n i š t  S ,  G v o z d j a k o v a  A .  ( 2 0 0 8 b ) .  I n  Mitochon-
drial medicine: mitochodrial metabolism, diseases, diagnosis and therapy. 
Gvozdjakova, eds, pp 340–342. Springer, Netherlands
Bauerova K, Paulovičova E, Mihalova D, Švík K, Poništ S. (2009). Study of new 
ways of supplementary and combinatory therapy of rheumatoid arthritis 
with immunomodulators. Glucomannan and Imunoglukán® in adjuvant ar-
thritis. Toxicology and Industrial Health 25(4–5): 329–335.
Bauerova K, Paulovičova E, Mihalova D, Dráfi   F, Štrosova M, Mascia C, Biasi F, 
Rovensky J, Kucharska J, Gvozdjakova A, Poništ S. (2010). Combined metho-
trexate and coenzyme Q10 therapy in adjuvant-induced arthritis evaluated 
using parameters of infl  ammation and oxidative stress. Acta Biochimica Po-
lonica 57(3): 347–354.
Boldyrev A. (2005). Protection of proteins from oxidative stress A new illusion 
or a novel strategy? Ann N Y Acad Sci 1057: 193–205.
Brown RK, Kelly FJ. (1996). Peroxides and other products. In: Free Radicals, a 
practical approach. Punchard NA, Kelly FJ, eds, pp 119–131. Oxford Univer-
sity Press, Oxford.
Cuzzocrea S, Mazzon E, di Paola R, Genovese T, Muià C, Caputi AP, Salvemini 
D. (2005). Synergistic interaction between methotrexate and a superoxide 
dismutase mimetic: pharmacologic and potential clinical signifi  cance. Ar-
thritis Rheum 52(12): 3755–60.
Dinarello CA, Moldawer LL. (2002). In Pro-infl  ammatory and anti-infl  amma-
tory cytokines in rheumatoid arthritis: a primer for clinicians. 3rd ed., pp 351, 
Thousand Oaks, CA: Amgen.
Drábikova K, Perečko T, Nosáľ R, Bauerova K, Poništ S, Mihalova D, Kogan G, 
Jančinova V. (2009). Glucomannan reduces neutrophil free radical produc-
tion in vitro and in rats with adjuvant arthritis. Pharmacological Research 
59(6): 399–403. 
Dráfi   F, Bauerova K, Valachova K, Poništ S, Mihalova D, Juránek I, Boldyrev A, 
Hrabárova E, Šoltés L. (2010). Carnosine inhibits degradation of hyaluronan 
induced by free radical processes in vitro and improves the redox imbal-
ance in adjuvant arthritis in vivo. Neuroendocrinol Lett 31(2): 96–100.
Genestier L, Paillot R, Quemeneur L, Izeradjene K, Revillard JP. (2000). Mecha-
nisms of action of methotrexate. Immunopharmacology 47: 247– 257.39
Also available online on PubMed Central
Interdisciplinary Toxicology. 2011; Vol. 4(1): 33–39
Copyright © 2011 Slovak Toxicology Society SETOX
Gvozdjakova A, Kucharska J, Tanaka S, Neradova B, Bauerova K. (2004). Coen-
zyme Q10 supplementation diff  erently modulated heart and skeletal mus-
cle mitochondrial function induced by adjuvant arthritis. Mitochondrion 4: 
20–21.
He YH, Zhou J, Wang YS, Xiao C, Tong Y, Tang JC, Chan AS, Lu AP. (2006). Anti-
infl  ammatory and anti-oxidative eff  ects of cherries on Freund’s adjuvant-
induced arthritis in rats. Scand J Rheumatol 35: 356–358.
Jančinova V, Perečko T, Nosáľ R, Košťálova D, Bauerova K, Drábikova K. (2009). 
Decreased activity of neutrophils in the presence of diferuloylmethane 
(curcumin) involves protein kinase C inhibition. Eur J Pharmacol 612(1–3): 
161–6.
Jančinova V, Nosáľ R, Lojek A, Číz M, Ambrozova G, Mihalova D, Bauerova K, 
Harmatha J, Perečko T. (2010). Formation of reactive oxygen and nitrogen 
species in the presence of pinosylvin – an analogue of resveratrol. Neuro-
endocrinol Lett. 31(2): 79–83.
Kogan G, Staško A, Bauerova K, Polovka M, Šoltés L, Brezova V, Navarova J, 
Mihalova D. (2005). Antioxidant properties of yeast (13)-β-D-glucan stud-
ied by electron paramagnetic resonance spectroscopy and its activity in 
adjuvant arthritis. Carbohydr Polym 61: 18–28.
Kogure T, Tatsumi T, Sato H, Oku Y, Kishi D, Ito T. (2010). Traditional herbal 
medicines (Kampo) for patients with rheumatoid arthritis receiving con-
comitant methotrexate: a preliminary study. Altern Ther Health Med 16: 46–
51.
Mačičkova T, Drábikova K, Nosáľ R, Bauerova K, Mihalova D, Harmatha J, 
Pečivova J. (2010). In vivo eff  ect of pinosylvin and pterostilbene in the ani-
mal model of adjuvant arthritis. Neuroendocrinol Lett 31(2): 91–95.
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni 
C, Leeb B, Elliott MJ, Woody JM, Schaible TF, Feldmann M. (1998). Therapeu-
tic effi   cacy of multiple intravenous infusions of anti-tumor necrosis factor 
a monoclonal antibody combined with low-dose weekly methotrexate in 
rheumatoid arthritis. Arthritis Rheum 41: 1552–1563.
McKendry RJ, Dale P. (1993). Adverse eff  ects of low dose methotrexate ther-
apy in rheumatoid arthritis. J Rheumatol 20(11): 1850–1856.
Moreland LW, Heck LW Jr, Koopman WJ. (1997). Biologic agents for treating 
rheumatoid arthritis: concepts and progress. Arthritis Rheum 40: 397–409.
Ondrejičkova O, Ziegelhoeff  er A, Gabauer I, Sotnikova R, Styk J, Gibala P , 
Sedlak J, Horákova L. (1993). Evaluation of ischemia-reperfusion injury by 
malondialdehyde, glutathione and gamma-glutamyl transpeptidase: lack 
of specifi  c local eff  ects in diverse parts of the dog heart following acute 
coronary occlusion. Cardioscience 4: 225–230.
Orlowski M, Meister A. (1970). The gamma-glutamyl cycle: a possible trans-
port system for amino acids. Proc Natl Acad Sci 67: 1248– 1255.
Perečko T, Jančinova V, Drábikova K, Nosáľ R, Harmatha J. (2008). Structure-
effi   ciency relationship in derivatives of stilbene. Comparison of resveratrol, 
pinosilvin and pterostilbene. Neuroendocrinol Lett 29: 802–805.
Poništ S, Mihalova D, Jančinova V, Šnirc V, Ondrejičkova O, Mascia C, Poli G, 
Stančikova M, Nosáľ R, Bauerova K. (2010). Reduction of oxidative stress in 
adjuvant arthritis. Comparison of effi   cacy of two pyridoindoles: stobadine 
dipalmitate and SMe1.2HCl. Acta Biochim Pol 57(2): 223–8.
Poništ S, Kucharska J, Gvozdjakova A, Komendova D, Mihalova D, Bauerova K. 
(2007). Mitochondrial bioenergetics of skeletal muscle studied in adjuvant 
arthritis. Chem Listy 101: 256–257.
Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, 
Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-
Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola 
E, Montecucco C, Schoels M, van der Heijde D. (2010). Treating rheumatoid 
arthritis to target: recommendations of an international task force. Ann 
Rheum Dis 69(4): 631–7.
Sotnikova R, Poništ S, Navarova J, Mihalova D, Tomekova V, Štrosova M, Bau-
erova K. (2009). Eff  ects of sesame oil in the model of adjuvant arthritis. Neu-
roendocrinol Lett 30: 22–24.
Rovensky J, Švík K, Stančikova M, Istok R, Ebringer L, Ferenčik M. (2002). Treat-
ment of experimental adjuvant arthritis with the combination of metho-
trexate and lyophilized Enterococcus faecium enriched with organic sele-
nium. Folia Microbiol 47: 573–578.
Rovensky J, Švík K, Rovenska E, Štvrtinova V, Stančikova M. (2008). Eff  ects 
of purifi  ed micronized fl  avonoid fraction (Detralex) on prophylactic treat-
ment of adjuvant arthritis with methotrexate in rats. Isr Med Assoc J 10: 
377–380.
Rovensky J, Stančikova M, Švík K, Bauerova K, Jurčovičova J. (2009a). The 
eff  ects of beta-glucan isolated from Pleurotus ostreatus on methotrex-
ate treatment in rats with adjuvant arthritis. Rheumatol Int doi: 10.1007/
s00296-009-1258-z
R o v e n s k y  J ,  S t a n č i k o v a  M ,  R o v e n s k a  E ,  Š t v r t i n a  S ,  Š t v r t i n o v a  V ,  Š v í k  K .  
(2009b). Treatment of rat adjuvant arthritis with fl  avonoid (Detralex), meth-
otrexate, and their combination. Ann N Y Acad Sci 1173: 798–804.
Sarban A, Kocyigit A, Yazar M, Isikan UE. (2005). Plasma total antioxidant ca-
pacity, lipid peroxidation, and erythrocyte antioxidant enzyme activities 
in patients with rheumatoid arthritis and osteoarthritis. Clin Biochem 38: 
981–986.
Štolc S, Bauer V, Benes L, Tichy M. (1983). Medicine with antiarrhythmic and 
antihypoxic activity and its method of preparation. Patents: CS 229 067, 
SWED. 8204693–9, BELG. 894148, SWISS 651 754, BRD P-3231088, SPAIN 553 
017, JAP. 151 4040.
Š troso va M, T omašk o va I, P oni št S, Bauero va K, Karlo vska J , Spick ett CM,  
Horákova L. (2008). Oxidative impairment of plasma and skeletal muscle 
sarcoplasmic reticulum in rats with adjuvant arthritis – eff  ects of pyridoin-
dole antioxidants. Neuroendocrinol Lett 29: 706–711.
Štrosova M, Karlovska J, Spickett CM, Országhova Z, Poništ S, Bauerova K, Mi-
halova D, Horákova L. (2009). Modulation of SERCA in the chronic phase of 
adjuvant arthritis as a possible adaptation mechanism of redox imbalance. 
Free Radic Res 43: 852–864.
Tastekin N, Aydogdu N, Dokmeci D, Usta U, Birtane M, Erbas H, Ture M. (2007). 
Protective eff  ects of L-carnitine and alpha-lipoic acid in rats with adjuvant 
arthritis. Pharmacol Res 56: 303–310.
Weinblatt ME. (2003). Rheumatoid arthritis in 2003: where are we now with 
treatment? Ann Rheum Dis 62(2): 94–6.
Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, 
Jackson CG, Lange M, Burge DJ. (1999). A trial of etanercept, a recombinant 
tumor necrosis factor receptor: Fc fusion protein, in patients with rheuma-
toid arthritis receiving methotrexate. N Engl J Med 340: 253–259.
Williams HJ, Willkens RF, Samuelson CO Jr, Alarcon GS, Guttadauria M, Yar-
boro C, Polisson RP, Weiner SR, Luggen ME, Billingsley LM, Dahl SL, Egger 
MJ, Reading JC, Ward JR. (1985). Comparison of low-dose oral pulse metho-
trexate and placebo in the treatment of rheumatoid arthritis: a controlled 
clinical trial. Arthritis Rheum 28: 721–730.